Vertex Pharmaceuticals announced this week that the European Commission has approved KALYDECO (ivacaftor) for people with cystic fibrosis ages 6 and older who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene...
The EU has approved Kalydeco, originally approved for CF patients with at least one copy of the G551D mutation, for 8 additional mutations including Patients with the G178R, S549N, S549R, G551S, G1244E, S1251N and S1255P.
Read the Vertex press release here.
The EU has approved Kalydeco, originally approved for CF patients with at least one copy of the G551D mutation, for 8 additional mutations including Patients with the G178R, S549N, S549R, G551S, G1244E, S1251N and S1255P.
Read the Vertex press release here.